Literature DB >> 25294697

Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma.

Ioana Cosgarea1, Zdenka Lovric1, Andreas Körber1, Joachim Dissemond2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25294697      PMCID： PMC7949558          DOI： 10.1111/iwj.12377

Source DB:  PubMed          Journal:  Int Wound J        ISSN： 1742-4801            Impact factor:   3.315


× No keyword cloud information.
  10 in total

1.  Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab.

Authors:  Ari M Goldminz; Nina C Botto; Alice B Gottlieb
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

2.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

3.  Investigation of new co-factors in 49 patients with pyoderma gangrenosum.

Authors:  Philipp Al Ghazal; Andreas Körber; Joachim Klode; Joachim Dissemond
Journal:  J Dtsch Dermatol Ges       Date:  2011-07-15       Impact factor: 5.584

4.  Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.

Authors:  Emmanuella Guenova; Anna Teske; Birgit Fehrenbacher; Sebastian Hoerber; Annette Adamczyk; Martin Schaller; Wolfram Hoetzenecker; Tilo Biedermann
Journal:  Arch Dermatol       Date:  2011-06-16

5.  Clinical features of pyoderma gangrenosum and current diagnostic trends.

Authors:  Ahmed Hadi; Mark Lebwohl
Journal:  J Am Acad Dermatol       Date:  2011-02-03       Impact factor: 11.527

Review 6.  Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.

Authors:  W P Daniel Su; Mark D P Davis; Roger H Weenig; Frank C Powell; Harold O Perry
Journal:  Int J Dermatol       Date:  2004-11       Impact factor: 2.736

Review 7.  Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.

Authors:  Jörg Reichrath; Guido Bens; Anette Bonowitz; Wolfgang Tilgen
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

8.  Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway.

Authors:  Nitza G Shoham; Michael Centola; Elizabeth Mansfield; Keith M Hull; Geryl Wood; Carol A Wise; Daniel L Kastner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

Review 9.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

10.  Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients.

Authors:  Philipp Al Ghazal; Katharina Herberger; Jörg Schaller; Anke Strölin; Norman-Philipp Hoff; Tobias Goerge; Hannelore Roth; Eberhard Rabe; Sigrid Karrer; Regina Renner; Jan Maschke; Thomas Horn; Julia Hepp; Sabine Eming; Uwe Wollina; Markus Zutt; Isabell Sick; Benno Splieth; Dorothea Dill; Joachim Klode; Joachim Dissemond
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123
  10 in total
  4 in total

Review 1.  Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Authors:  Klaus Eisendle; Tobias Thuile; Jenny Deluca; Maria Pichler
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-04-28       Impact factor: 4.730

Review 2.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

Review 3.  Pyoderma gangrenosum: challenges and solutions.

Authors:  Ana Gameiro; Neide Pereira; José Carlos Cardoso; Margarida Gonçalo
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-05-28

Review 4.  Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.

Authors:  Sahil Rawal; Sara Kianian; William Guo; Jocellie Marquez; Marissa Ayasse; Katherine A Siamas; Yoojin Lee; Joann Salvemini
Journal:  Arch Dermatol Res       Date:  2021-06-22       Impact factor: 3.017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.